Abstract: The disclosure relates to a protein-type nanoparticle for multi-specific antibody delivery, a preparation method, and its application. The protein-type nanoparticle includes a polyester and a protein with a hydrophobic domain, and the hydrophobic domain of the protein is bound with the polyester through hydrophobic interactions. The protein is at least one of albumin, globulin and cell wall protein. The protein-type nanoparticle of the present disclosure has excellent stability and biocompatibility. The protein-type nanoparticle is used to prepare a multi-specific antibody delivery platform (?Fc-NP) by binding anti-IgG-Fc antibody or anti-IgG-Fc antibody fragment, which can stably, quickly and easily bind to multiple specific antibodies through antigen-antibody interaction and enhance the therapeutic effect of specific antibodies.
Type:
Grant
Filed:
January 27, 2023
Date of Patent:
April 16, 2024
Assignee:
SOUTH CHINA UNIVERSITY OF TECHNOLOGY
Inventors:
Jun Wang, Zhiting Cao, Song Shen, Qianni Ye, Xiaojiao Du, Xianzhu Yang, Youyong Yuan
Abstract: Methods of inducing an immune response comprising at least two administrations of an adjuvanted immunogenic composition, wherein the second administration contains reduced amounts of antigen and adjuvant.
Type:
Grant
Filed:
March 11, 2020
Date of Patent:
April 9, 2024
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
William Ripley Ballou, Jr., Arnaud Michel Didierlaurent, Robbert Gerrit Van Der Most
Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
Abstract: The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.
Abstract: Polymeric nanoparticles comprising a defined set of biologically active agents that provide for targeted stimulation of non-responsive T cells, e.g. T cells involved in cancer, are provided.
Abstract: Methods and kits for purifying protein-nanoparticle conjugates are provided. In some embodiments, a multimodal medium having a size exclusion mode and a capture mode is used to purify the protein-nanoparticle conjugates.
Abstract: This disclosure relates to methods for improving the therapeutic index of a chemotherapeutic drug in the treatment of patients afflicted with cancer, including, for example, reducing chemotherapy-related toxicity (e.g., liver toxicity).
Type:
Grant
Filed:
March 21, 2017
Date of Patent:
January 23, 2024
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.
Abstract: Disclosed herein are methods and platforms for increasing utility and efficacy of a cellular vaccine. Specifically, disclosed are steps that optimize ex vivo B cell expansion and boost host in vivo immunity. Also disclosed is a platform for enhancing effectiveness of antigen presentation and antigen-specific immune responses. Also disclosed is a method for enhancing effectiveness of APCs in a subject. Also disclosed are vaccines and kits based on the platform.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
December 26, 2023
Assignee:
Ohio State Innovation Foundation
Inventors:
Thomas L Cherpes, Nirk E. Quispe Calla, Rodolfo Daniel Vicetti Miguel
Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
November 28, 2023
Assignee:
NORTHWESTERN UNIVERSITY
Inventors:
Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
November 21, 2023
Assignee:
EAGLE BIOLOGICS, INC.
Inventors:
Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
November 7, 2023
Assignee:
COMERA LIFE SCIENCES, INC.
Inventors:
David S. Soane, Philip Wuthrich, Rosa Casado Portilla, Robert P. Mahoney, Mark Moody, Daniel G. Greene
Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.
Type:
Grant
Filed:
May 30, 2018
Date of Patent:
August 15, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Lori S. Burton, William Ying, Nils Lonberg, Sudhir Chakravarthi, Pedro Smith
Abstract: The present invention relates to a lyophilization process for preparing a teverelix-TFA lyophilizate, said process comprises the following steps: a) providing a lyophilization suspension by mixing teverelix and trifluoroacetate at a molar ratio sufficient for providing a microcrystalline teverelix-TFA suspension without formation of a gel, and b) lyophilizating the lyophilization suspension, thereby providing a teverelix-TFA lyophilizate. The process provides the possibility of obtaining a “pure” teverelix-TFA lyophilizate i.e. without any undesirable residues in the composition.
Abstract: Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.
Type:
Grant
Filed:
March 19, 2020
Date of Patent:
July 18, 2023
Assignee:
The Research Foundation for The State University of New York
Inventors:
Sathy Balu-Iyer, Richard Bankert, Radha Ramakrishnan, Robert Dingman, Vandana Iyer, Jennifer Schneider, Fiona Yau Glassman, Nhan Hanh Nguyen